Christopher L. Cioffi

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 368 citations

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 276 citations

Systemic Treatment, Clinical Trials, Bimekizumab Versus Ustekinumab +6

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B. Gordon, Peter Foley, James G. Krueger et al. · The Lancet · 2021 · 258 citations

Systemic Treatment, Bimekizumab Efficacy, Clinical Trials +6

Bimekizumab versus Adalimumab in Plaque Psoriasis

Richard B. Warren, Andrew Blauvelt, Jerry Bagel et al. · New England Journal of Medicine · 2021 · 217 citations

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

Kim Papp, Joseph F. Merola, Alice B. Gottlieb et al. · Journal of the American Academy of Dermatology · 2018 · 187 citations · Full text